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AntibiofoulingAbstract Biofouling is a serious problem and very difﬁcult to overcome, since the marine bioﬁlm-
producing microorganisms resist the host defense mechanism and antibiotic therapy. Therefore,
there is an urgent need to develop potent anti-biofouling agent to effectively eradicate unwanted
bioﬁlms. Our work represents antibacterial susceptibility and antibioﬁlm forming assay of new
copper(II) N-pyruvoyl anthranilate architectures (4a–d) against Staphylococcus aureus and
Escherichia coli, marine isolates. The preliminary bioﬁlm susceptibility tests revealed that, the most
potent staphylococcalcidal (MIC/MBC= 9.25/10.50 mM) and E. coli-cidal (MIC/MBC =
13.25/13.50 mM) agent, 4d, exhibits signiﬁcant bioﬁlm inhibition. Complex 4d can therefore pro-
vide an antibioﬁlm-forming agent candidate to curb the formation of bioﬁlms.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Interestingly, a-Keto amides formed from reaction of
(Het)aroylpyruvic acid esters with amines, to formaroylpyruvic acid amides, offer various drug-design opportuni-
ties and important suitable alternative approaches for the
delivery of biologically active compounds, for examples in
anti-inﬂammatory (Koz´minykh et al., 1992), antibacterial
(Milyutin et al., 1997; Yanborisov et al., 1989), analgesic and
antispasmodic, chemotherapy with extraordinarily low toxicity
(Koz´minykh et al., 2002). Furthermore, oxanilic acids have
been reported as inhibitors of protein-tyrosine phosphatase
1B (PTP1B) (Andersen et al., 2002; Iversen et al., 2001),
T-cell protein-tyrosine phosphatase (Iversen et al., 2002) and
the tyrosine kinase p56lck SH2 domain (Beaulieu et al.,
1999). Oxanilic acid esters have been found to be potent orally
active antiallergy agents (Sellstedt et al., 1975; Wright and
Johnson, 1977; Klaubert et al., 1981; Hargrave et al., 1983).
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tution of the sarcosine residue of sarmesin with oxanilic acid
yields analogues (Scheme S1, supplementary information) with
angiotensin antagonist activity.
Also, 2-thenoyl derivatives, as therapeutic agents, exhibit
interesting pharmaceutical properties including antimicrobial
(Queiroz et al., 2006), anticancer (Thomson et al., 2006),
HIV protease inhibitor nelﬁnavir (Bonini et al., 2004), HIV-
PR inhibitors (Bonini et al., 2005), antiinﬂammatory (Kumar
et al., 2004), bacteriostatic and fungistatic activities (Kipnis
et al., 1949). Furthermore, they exhibit strong inhibition of
NHE-1, cardio-protective efﬁcacy (Lee et al., 2005) and anti-
cancer activity against human renal cells (Nieves-Neira et al.,
1999). As well, they are important constituents of many drugs
such as methapyrilene, tenidap, tienilic acid and temocillin
(Rance and Damani, 1989) (Fig. S1, supplementary informa-
tion). Consequently, conjugation of pyruvoyl and 2-thenoyl
fragments may offer a platform of new antibiotic which syner-
getic effect of both pharmacophores.
Notably, metal ions not only accelerate the drug action but
also enhance the efﬁcacy of the therapeutic agents (Siddiqi
et al., 2010). More speciﬁcally, metal ions either penetrate into
bacterial stain and deactivate their enzymes or generate hydro-
gen peroxide, thus killing bacteria. Memorable, Cu(II) com-
plexes are known to have a broad spectrum of biological
action (Suksrichavalit et al., 2009; Rosu et al., 2010; Kulkarni
et al., 2010; Parmar and Kumar, 2009). Currently, the copper
compounds used as antifoulants such as metallic copper,
cuprous thiocyanate, and cuprous oxide (Comber et al., 2002;
Iwao, 2003; Karkhanechi et al., 2013) where the cupric ion
(Cu2+) has a major role in antifouling performance in fouling-
ﬁghting paints (Yebra et al., 2004). However, the major draw-
back of copper-based antifouling paint is, the extractable copper
concentration in sediment from ﬁsh farms using anti-fouling
treatment was 2–3 times higher than from those using untreated
nets (Nikolaou et al., 2014). Consequently, the use of anti-
fouling paints with inorganic copper additive may be a potential
source of copper accumulation in cultured ﬁsh. So, researching
for new copper alternatives antifouling additives is a topic of
increasing interest. To the best of our knowledge, there are a
few reports on evaluation of Cu(II) complexes as antifouling
agents (Rajalakshmi et al., 2014; Ahmed et al., 2014; Bayer
et al., 2011; Hemaida et al., 2008), which give this area excep-
tional interest to specialist researchers in the ﬁeld of antifouling.
In the context of our ongoing programs directed toward the
development of novel, potent, selective and less toxic therapeu-
tic agents (Wisser and Janiak, 2007; Elshaarawy et al., 2008,
2014; Chamayou et al., 2011; Elshaarawy and Janiak,
2014a,b) and an extension of our previous work on the synthe-
sis thiophen-2-yl derivative (Elshaarawy et al., 2014, 2013;
Refat et al., 2014; Elshaarawy and Janiak, 2012; Mahmoud
and Janiak, 2009), herein, we now report a concise, practical
synthetic route and in vitro antimicrobial evaluation as well
as anti-biofouling nature of novel thenoylpyruvanthranilic
acids (Scheme 1) and their Cu(II) complexes which may be
promising antibiotic/anti-biofouling candidates.2. Experimental
Instrumentation, materials and the preparation details of a ser-
ies of thenoyl-pyruvoyl-anthranilic acid ligands (2a–d) andenaminones (3a–e) can be found in electronic supplementary
information.
2.1. Synthesis of the complexes
Generally, 2.0 mmol of the ligand TPAH2 or TPXAH2 (cf.
Scheme 1) was dissolved in 15 mL of absolute ethanol with a
constant stirring/gentle heating. To this solution, 0.399 g
(2.0 mmol) of Cu(OAc)2ÆH2O in 10 mL of water was added
dropwise with continuous stirring and the pH of the reaction
mixture was adjusted to neutral (pH  6.8) by use of 0.1 M
NaOH solution. The reaction mixture was heated under reﬂux-
ing for 4 h. After cooling slowly, the green precipitates were
separated out. The separated compound was ﬁltered, washed
thoroughly with absolute ethanol and water, and then dried
in a vacuum desiccator with P2O5. Unfortunately, many
attempts to grow single crystals of these complexes were
unsuccessful.
[Cu(TPA)H2O](4a): Yield 83%. FT-IR (ATR, cm
1):
3517 (m, br, m(OAH), H2O), 3257 (m, br, m(NAH), NHCO),
1675 (s, sh, m(C‚O), amide I), 1576 (w, sh, m(C‚CAC‚O)), 1516
(m, sh, masðCOOÞ), 1496 (s, sh, m(CN) + d(NAH), amide II), 1460
(m, sh, msðCOOÞ), 1351 (m, sh, m(CSC), thiophene), 1062 (m, sh,
m(CO), COO
), 858, 653, 464; EI-MS m/z calcd for
C15H11NO5S: 396.86, found: 396.78. Anal. Calcd. for
C15H11CuNO6S (M= 396.86 g/mol): C, 45.40; H, 2.79; N,
3.53; S, 8.08, found: C, 45.44; H, 3.00; N, 3.47; S, 8.23%.
[Cu(TPCA)H2O](4b): Yield 81%. FT-IR (ATR, cm
1):
3444 (m, br, m(OAH), H2O), 3330 (m, br, m(OAH), H2O), 3269
(m, br, m(NAH), NHCO), 1592 (s, sh, m(C‚O), amide I), 1565
(w, sh, m(C‚CAC‚O)), 1495 (m, sh, masðCOOÞ), 1445 (m, sh,
msðCOOÞ), 1352 (m, sh, m(CSC), thiophene), 1083 (m, sh, m(CAO),
COO), 876, 674, 465; EI-MS m/z calcd for
C15H10ClNO6SCu: 431.30, found: 431.31; Anal. Calcd. for
C15H11CuNO6S (M= 431.30): C, 41.77; H, 2.34; N, 3.25; S,
7.43, found: C, 42.03; H, 2.32; N, 3.23; S, 7.38%.
[Cu(TPBA)H2O]ÆH2O(4c): Yield 77%. FT-IR (ATR,
cm1): 3488 (m, br, m(OAH), H2O), 3330 (m, br, m(OAH), H2O),
3229 (m, br, m(NAH), NHCO), 1609 (s, sh, m(C‚O), amide I),
1571 (w, sh, m(C‚CAC‚O)), 1490 (m, sh, masðCOOÞ), 1412 (m,
sh, msðCOOÞ), 1350 (m, sh, m(CSC), thiophene), 1060 (m, sh,
m(CAO), COO
), 858, 661, 463; EI-MS m/z calcd for
C15H12BrNO7SCu: 431.30, found: 431.31. Anal. Calcd. for
C15H12BrCuNO7S (M= 493.77): C, 36.49; H, 2.45; N, 2.84;
S, 6.49, found: C, 36.38; H, 2.43; N, 2.39; S, 6.73%.
[Cu(TPNA)(H2O)2](4d): Yield 68%. FT-IR (ATR,
cm1): 3447 (m, br, m(OAH), H2O), 3332 (m, br, m(OAH), H2O),
3176 (m, br, m(NAH), NHCO), 1588 (s, sh, m(C‚O), amide I),
1556 (w, sh, m(C‚CAC‚O)), 1489 (m, sh, masðCOOÞ), 1425 (m,
sh, msðCOOÞ), 1355 (m, sh, m(CSC), thiophene), 1081 (m, sh,
m(CAO), COO
), 846, 665, 459; EI-MS m/z calcd for
C15H12CuN2O9S: 459.87, found: 459.79. Anal. Calcd. for
C15H12CuN2O9S (M= 459.87): C, 39.18; H, 2.63; N, 6.09;
S, 6.97, found: C, 39.50; H, 2.71; N, 6.10; S, 6.84%.
2.2. X-ray crystallography
A single crystal with the dimensions of 0.06 · 0.21 · 0.17 mm3
of ethyl 2-thienyl-2-(2-carboxyanilino)-4-oxobutenoate (3b)
was carefully selected under a polarizing microscope and
mounted on a Rigaku R-axis Spider diffractometer equipped
Scheme 1 Signiﬁcant pharmacological sites in thenoyl–pyruvoyl-anthranilic acids (TPXAH2, 2a–d) and enaminones (3a–e) used in this
work.
Table 1 Crystal data and structure reﬁnement for 2b.
Empirical formula C41H36N3O12S2
Formula weight 826.85 g mol1
Temperature (K) 296(2)
Crystal system Triclinic
Space group P  1 (2)
a (A˚), b (A˚), c (A˚) 9.5657(3), 10.2949(3), 11.3068(3)
a, b, c () 87.32(0), 77.17(0), 67.33(0)
Volume (A˚3) 1000.84(48)
Z 1
qcalc (g cm
3) 1.37178
Antibacterial susceptibility of new copper(II) N-pyruvoyl anthranilate complexes 827with sealed tube graphite-monochromatic Mo Ka radiation
sources (k= 0.71073 A˚) and image plate (IP) detector. The
structure was solved by direct methods (SHELXS-97)
(Sheldrick, 2008) and reﬁned using full-matrix least squares
on F2 using the SHELXL-97 program (Sheldrick, 2008);
empirical (multi-scan) absorption correction with Abscor
(Rigaku) (Higashi, 1995). All non-hydrogen atoms were
reﬁned with anisotropic temperature factors. At the ﬁnal stage
of the reﬁnement, H-atoms were positioned geometrically and
reﬁned using a riding model (AFIX 43 for aromatic CH, AFIX
13 for aliphatic CH and AFIX 23 for CH2) with
Uiso(H) = 1.2Ueq(CH). For CH3 AFIX 33, 133 or 137 was
used with Uiso(H) = 1.5Ueq(CH3). The carboxylic H atom
has been reﬁned with the riding model AFIX 83 and
Uiso(H) = 1.5Ueq(O). The imine H atom has been reﬁned with
the riding model AFIX 43 while the amino nitrogen atoms of
2-aminobenzoic acid have been reﬁned with the riding model
AFIX 93. In both cases the (NA)H atoms have been reﬁned
with Uiso(H) = 1.5Ueq(O). The thiophene ring (Th) is disor-
dered about the (O)CAC(Th) bond, depicted in Fig. 1. This
thiophene disorder was reﬁned using a PART command.
The asymmetric unit contains half molecule of
2-aminobenzoic acid. The 2-aminobenzoic acid co-crystallite
sits on the inversion center as special position. Its unique atoms
were reﬁned using PART-n commands because the molecule is
disordered on a special position of higher symmetry than theFigure 1 (a) Typical sulfur atom or thiophene ring disorder
in the planar ligand and (b) resulting superimposed image in an
X-ray structure reﬁnement with approximately half-occupation
of the given (5-)C- and S-atom positions.molecule has itself. Thus, special position constraints are sup-
pressed and bonds to symmetry generated atoms with the same
or a different non-zero PART number are excluded. The crys-
tallographic data and reﬁnement parameters are listed in
Table 1 (Tables S2, S3, supplementary information).
Graphics were drawn with DIAMOND (Brandenburg, 2007–
2012).
2.3. Microbiological screening
2.3.1. Antibacterial survey
2.3.1.1. Reagents. Dimethylsulfoxide (DMSO) and Ampicillin
antibiotic (C16H19N3O4S, 349.41 g mol
1) were obtained from
Sigma Chemical Co. (St. Louis, MO, USA).F(000) 431
Crystal size 0.06 · 0.21 · 0.17
Theta range for data
collection
3.37–27.35
Index ranges 11 6 h 6 11, 12 6 k 6 12,
13 6 l 6 13
Reﬂections collected 16,978
Independent reﬂections 3865 [Rint = 0.0251]
Reﬁnement method Full-matrix least-squares on F2
Data/restraints/parameters 3865/0/308
Goodness-of-ﬁt on F2 1.073
Final R indices [I> 2r(I)] R1 = 0.0373, wR2 = 0.0924
R indices (all data) R1 = 0.0648, wR2 = 0.1141
Largest diﬀ. peak and hole 0.22 and .24 e A˚3
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used in this study from National institute of oceanography
and ﬁshery (NIOF), Suez, Egypt. The different strains are
penicillin sensitive Staphylococcus aureus (PSSA) as represen-
tatives for the Gram-positive bacteria and MDREC
(multidrug-resistant Escherichia coli) (E. coli, amoxicillin/
clavulanate, trimethoprim/sulfamethoxazole and ﬂuoro-
quinolone-resistant isolates) as the most important Gram-
negative pathogenic bacteria. Stock cultures grown aerobically
on nutrient broth (NB) agar slants (Hi-Media) at 37 C were
maintained at 4 C. Pre-cultures containing 105 CFU/ml,
grown aerobically in Mueller Hinton (MH) liquid medium
(Hi-Media) at 37 C for 5 h, were used as inoculum for all
experiments.
2.3.1.3. Antimicrobial susceptibility. Antimicrobial susceptibil-
ity of the bacterial strains was carried out by agar well diffu-
sion method (Perez and Bazerque, 1990) toward the target
compounds as well as standard drugs, Ampicillin. The diame-
ter of the zones of inhibition (ZOI, mm) was measured accu-
rately as indicative of antimicrobial activity.
2.3.1.4. Determination of MIC and MBC. As parameters of the
antibacterial efﬁcacy, the minimal inhibitory concentration
(MIC) and minimal bactericidal concentration (MBC) of the
most potent compounds, Cu(II) complexes (4a–d), against
infection isolates were determined using the macro-dilution
broth susceptibility test. Freshly prepared MH broth was used
as diluent in the macro-dilution method. A serial dilution of
each target compound was prepared within a desired range
(0.25–20.00 mM). One milliliter of the Stock cultures was then
inoculated and tubes were incubated at 37 C for 24 h, control
tubes without any addition were assayed simultaneously. MIC
was examined visually, by checking the turbidity of the tubes.
Furthermore the tubes having lesser concentration than MIC
level were inoculated on MHA plate for MBC determination.2.3.2. Bioﬁlm susceptibility test by Alamar blue method
Whereas, bioﬁlm growth can be used as indicator of biofouling
where the sequence of bioﬁlm formation includes (a) adsorption
of organic maters and suspended particles on the wetted surface
to form a conditioning ﬁlm; (b) moving of the microbial cells
toward the conditioning ﬁlm and adhesion to the surface; (c)
growth and metabolism of the attached microorganisms
and bioﬁlm/biofouling development (Nguyen et al., 2012).
Consequently, bacterial bioﬁlm formation and antibiotic sus-
ceptibility could be used for monitoring surface biofouling.
This test was performed in 96-well non-tissue culture trea-
ted microtiter plate. The wells of the titer plate were ﬁlled with
nutrient broth and inoculated using bacterial culture (0.1
absorbance at 600 nm) so that the ﬁnal volume comes to
100 mL. Plates were incubated at 37 C for 24 h without shak-
ing. Complexes were incubated with sterile medium, Cation-
Adjusted (Mueller Hinton II. Broth, MHIIB), and DMSO
(9:1) external to the plates. After incubation, 50 mL of the sus-
pension was discarded from all the control and test wells and
50 mL of the complex of varying concentration was added
(0.25–20 mM). The plates were incubated at 37 C for 24 h
with shaking. After incubation 5 mL of Alamar blue was
added to the wells and the plate was incubated at 37 C for
1 h with gentle shaking. Absorbance at 570 and 600 nm wasrecorded using Tecan Inﬁnite M 200 Elisa reader. Positive
and negative controls (media alone, media plus AB and cells
plus media plus AB) were maintained along with the test
(Pettit et al., 2005). The percent reduction of Alamar blue
was calculated as follows;
%Reduction of Alamar blue¼ ðeoxÞk2Ak1  ðeoxÞk1Ak2ðeredÞk2A0k1  ðeredÞk1A0k2  100
ð1Þ
here, eox = molar extinction coefﬁcient of Alamar blue in oxi-
dized form (blue) ered = molar extinction coefﬁcient of Alamar
blue in reduced form (pink), A= absorbance of test wells,
A0 = absorbance of negative control well, k1 = 570 nm,
k2 = 600 nm, eox = 117,216 at 600 nm and 80,586 at 570 nm,
ered = 14,652 at 600 nm and 155,677 at 570 nm.
Notably, although the Alamar blue (AB) reduction method
for monitoring biofouling has provided useful information
regarding the early formation of bioﬁlms, to date it cannot dif-
ferentiate between the planktonic growth, bioﬁlm progress and
other components deposited on the surface, and cannot pro-
vide detailed microbiological/chemical information about the
bioﬁlm, therefore their assistance in the development and opti-
mization of efﬁcient anti-fouling strategies is limited.
3. Results and discussion
3.1. Synthesis and characterization of ligands
Choosing an appropriate solvent is of crucial importance not
only for successful synthesis but also for the effective control
of chemoselective reactions. For example, 2-thenoyl-pyruvate
1b reacted with equimolar amounts of anthranilic acid deriva-
tives in HOAc/EtOH (few drops of HOAc) mixed-solvent sys-
tem to give thenoyl–pyruvoyl-anthranilide products (a-keto
anthranilides). However, if HOAc is used alone, the thienyl-car
boxyphenylamino-butenoates (enaminones) were obtained as
the main products. Under these optimized chemoselective con-
ditions, a series of thenoyl–pyruvoyl-anthranilic acids (2a–d)
and enaminones (3a–e) were synthesized via two component
reactions of 2-Thenoyl-pyruvate 1b and different anthranilic
acid derivatives in a mixed-solvent, HOAc/EtOH and single-
solvent, HOAc, respectively (see Scheme 2). These compounds
have been characterized based on FT-IR, 1H and 13C NMR,
elemental analysis and single crystal XRD.
In order to extend the present method to synthesize
different enaminones, the aminolysis of thenoyl-pyruvate with
different substituted anthranilic acids was explored.
Interestingly, the presence of an electron-withdrawing group
on the phenyl ring requires longer reaction times with slightly
decreased yields.
FTIR spectra of thenoylpyruvanthranilic acids (2a–d)
revealed the following highlights: (i) Absorptions at the ranges
of 3395 ± 25 cm1 and 1603 ± 27 cm1 are assignable to the
hydroxyl and carbonyl groups stretching vibrations of enolic
structural unit (O‚CAC‚CAOH), respectively. (ii) A broad
peak for the NAH stretch of the oxamido group is observed in
the range of 3203–3324 cm1 due to the involvement of amide
proton in hydrogen bonding (Krishnapriya et al., 2008). (iii)
The broad band centered in the range of 2517–2645 cm1 is
assigned to H-bonded OH stretching frequency of the carboxyl
moiety which exhibits additional band, due to carbonyl
Scheme 2 Chemoselective aminolysis of thenoyl-pyruvate with different substituted anthranilic acids.
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range of 1662 ± 8 cm1, 1602 ± 28 cm1 and 1513 ± 5 cm1
were ascribed to the vibrational stretches of the amide I
(mC‚O of oxamide) (Nakamoto, 1997), amide II
(dNAH + mC‚N) and amide III (mCAN + dNAH), respectively
(Sahni et al., 1997).
The NMR studies of thenoylpyruvanthranilic acids (2a–d)
showed that, different substituents on benzoic acid fragment
reveal diverse central backbone NMR proﬁles. For example
in TPAH2 (2a), no substituent, the different central backbone
is in the enol-oxo-amide tautomeric form and not in the dioxo-
amide (keto-oxo-amide) form (Scheme 3). Furthermore, this
tautomer must be considered as (Z)-enol-c-oxo-amide struc-
ture as revealed by 1HA1H COSY NMR. The prevalence of
the (Z)-enol-c-oxo-amide resonance structure in TPAH2
ligand could be attributed to intramolecular hydrogen bonding
(C‚O  HAN) of the enol-c-oxo-amide arms which led to the
formation of a stable six-membered ring system. The 1H NMR
spectrum of TPAH2 (Fig. S2, supplementary information)
exhibits resonances at d 12.07 ppm for enolic C(8)AOH and
at 6.70 ppm for C(7)–vinylic proton typical for enol-oxo-
amide form (Belyaev et al., 2002). Further evidence for the
prevalence of enolic tautomer is provided by 13C NMR spec-
troscopy, where the absence of NMR signal for the methylene
carbon in 13C NMR spectrum of TPAH2 and instead a vinylic
carbon signal of the enol-oxo-amide form appears at
d  99 ppm in addition to the downﬁeld signal in the region
d  188 ppm for the enolic carbon.
Contrarily, 1H NMR spectrum of TPBAH2 (Fig. S3, sup-
plementary information) reveals two singlets at 12.43 ppm
for enolic OH and 7.18 ppm for vinylic proton, typical for
oxo-enamide tautomeric form of ligand. The singlet at4.63 ppm, ascribed to geminal CH2 protons, is also typical
for dioxo-amide form of TPBAH2. Consequently, this ligand
must be considered as a resonance hybrid of the (Z)-enol-c-
oxo-amide resonance structure with some contribution of the
dioxo-amide resonance structure (Belyaev et al., 2002) (cf.
Scheme 3). 13C NMR provides additional evidence supporting
the coexistence of the oxoenamide – dioxoamide tautomers.
The 13C NMR spectrum of TPBAH2 exhibits a weak reso-
nance at 60 ppm for the methylene carbon and strong signal
at 107 ppm for a vinylic carbon of the enol form, addition-
ally, the downﬁeld signal in the region 189 ppm for the enolic
carbon and the carbonyl C‚O signal of the dione form at
181 ppm.
The 1HA1H COSY NMR (Fig. S4, supplementary informa-
tion) shows the broadened non-coupled singlet at d 12.3 ppm,
which has been assigned as an enolic OH. This indicates that
the enolic proton at a considerable distance from thiophene
moiety, which suggests that only one tautomeric enol form
of the ligands exists in solution under the experimental condi-
tions (enol-c-oxo-amide).
3.1.1. Crystallographic structure of (3b)
X-ray crystallographic data indicates the co-crystallization of
ethyl 2-thienyl-2-(2-carboxyanilino)-4-oxobutenoate (ETCAOB)
with 2-aminobenzoic acid (anthranilic acid, Anth). ETCAOB
and Anth form a 2:1 co-crystal of 3b in the triclinic space
group P  1 with Z= 1. The asymmetric unit consists of
two ETCAOB and one Anth molecules (Fig. S5, supplemen-
tary information). H-bonding is dominant interactions in the
single crystal structure of 3b. Major H-bonding interactions
(Fig. 2) involved N1AH  O1 (distance of 2.14 A˚) and
N1AH  O4 (distance of 2.05 A˚) in ETCAOB fragment.
Scheme 3 Possible tautomeric forms and intramolecular hydrogen-bonding in backbone of thenoylpyruvanthranilic acids.
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form, Noteworthy, the O‚CAC‚CAN moiety is planar
and the bond lengths indicate electron delocalization. The
O‚CAC‚CAN plane is twisted with respect to the benzene
and thienyl rings by 34.76(48) and 21.06(87), respectively.
Furthermore, the O‚CAC‚CAN plane and the O‚CAO
plane make a dihedral angle of 34.96(17).3.2. Synthesis and characterization of Cu(II) complexes
Mononuclear Cu(II) complexes of anthranilides (2a–d) have
been synthesized from a typical synthetic procedure in which,
Cu(OAc)2ÆH2O is reacted with dianionic (Z)-enol-c-oxo-
amide core of anthranilide ligands in aqueous ethanol as
shown in Scheme 4. These complexes are soluble in DMSO
and DMF, slightly soluble in methanol while fairly insoluble
in water. The structural and geometrical features of the new
complexes were deduced from the elemental and spectral
(FTIR, UV–Vis, EIMS) analysis (see Section 2).
FTIR spectra of complexes (4a-d) displayed a set of bands
at ca. 1588–1560 cm1 and 1410–1362 cm1 assignable to the
asymmetric mas(COO
) and symmetric ms(COO
) vibrations
of coordinated carboxylate group, respectively. The frequencyFigure 2 Ellipsoid plot of the Z-ETCAOB, showing the atom-
labeling scheme and H-bonding interactions.gaps (Dm) between these bands have an average of 217 cm1
which is consistent with a monodentate coordination mode
(g1) of carboxylate ligation (Elshaarawy et al., 2014, 2013;
Refat et al., 2014; Elshaarawy and Janiak, 2012; Mahmoud
and Janiak, 2009). The absence of the characteristic bands
at 1730–1690 cm1 for protonated carboxylate and
1603 ± 27 cm1 for enolate groups indicates the complete
deprotonation of the anthranilides ligands which proof that,
all ligands coordinate through carboxylate and enolate oxygen
atoms. The absence of any signiﬁcant change in amide I,
mC‚O, coupled with a negative shift (17–52 cm1) of the
amide NH band (relative to the free ligand) proofs the coordi-
nation the amide nitrogen. This further conﬁrmed by the
movement of amide II stretch upon coordination toward lower
frequency by 22–28 cm1 (compared to that of free ligand).
Moreover, a wide strong band (3500–3300 cm1) and new
band at 856–866 cm1 are due to the OAH stretching and
qrOH vibrations, respectively, of the coordinated water mole-
cule. Finally, the m(CSC) vibration remains almost unper-
turbed in all complexes indicating the non-participation of
the sulfur atom in coordination (Elshaarawy and Janiak,
2012). Consequently, our FTIR data revealed that, the anthra-
nilides (2a–d) ligands act as ONO tridentate dianionic ligands.
In order to explore the ligand to copper stoichiometric
ratios, the UV–Vis titration of TPAH2 ligand with Cu(II) salt
was carried out in aqueous DMSO (9:1 v/v) at 25 C. Here we
take TPAH2 as representative of these tridentate ligands. As
shown in Fig. 3, the 1:1 stoichiometry for the Cu(II)-TPAH2
complexation was elaborated by the proﬁle of the UV titration
curve at 406 nm. These results were in good agreement with
those deduced from the elemental analysis and EI-MS studies
of complexes 4a.
The electronic spectra of mononuclear Cu(II) complexes
4a–c in aqueous DMSO are almost identical. The most charac-
teristic feature of the UV–Vis spectra for these complexes is the
broad absorption band in the wavelength range of 369–475 nm
which can be assigned to the spin-allowed d-d transition,
2B1gﬁ 2Eg. This assignment suggests the square planar geom-
etry for Cu(II) complexes under investigation with [CuO3N]
core (Lever, 1984; Khana et al., 2009). On the other hand,
the electronic spectrum for a ﬁve coordinate Cu(II) compound
(4d) exhibits absorption band near 690 nm due to 2B1gﬁ 2A1g
transition supporting an approximate square pyramidal geom-
etry around Cu(II) ion with [CuO4N] core (Lever, 1984).
Scheme 4 Coordination of Cu(II) ion to thenoylpyruvanthranilic acids.
Figure 3 UV–Vis spectra for titration of TPAH2 (5 · 105 M)
with Cu2+ ion (5 · 103 M) in 10% DMSO aqueous solution at
r.t.
Antibacterial susceptibility of new copper(II) N-pyruvoyl anthranilate complexes 8313.3. Antibacterial activity proﬁle
The target anthranilides (2a–d), enaminones (3a–e), complexes
(4a–d) and standards drugs were in vitro assessed separately for
their capacity to inhibit the growth of two clinically signiﬁcant
pathogenic bacterial strains namely PSSA (S. aureus) and
MDREC (E. coli). Examination of the ZOI (mm) (Table S1,
supplementary information) (Fig. 4), MIC and MBC (mM)
values (Table 2) for the most potent compounds, (4a–d), lead
us to highlight the following aspects: (i) All compounds exhibit
signiﬁcant antibacterial efﬁcacy with a higher degree of
antistaphylococcal potency than antiescherichia activity and
are therefore of interest as potential antistaphylococcal agents.
(ii) Noteworthy, the enaminones (3a–e), ester derivatives, are
more potent than the anthranilides (2a–d), amide analogues,
while less active than the amide complexes (4a–d). (iii) The
antibacterial susceptibility was found to depend on the natureof the substituent attached to the anthranilic moiety. For
example, the substituent-dependent antibacterial activity of
[Cu(TPBA)(H2O)n]ÆmH2O (4a–d) against S. aureus and
E. coli follows the trend below:
X (MIC/MBC mM)S. aureus: NO2 (9.25/10.50) > Cl
(12.50/14.75)  Br (12.25/15.25) > H (13.75/18.75),
X (MIC/MBC mM)E. coli: NO2 (13.25/13.50) > Br
(14.75/14.75)  Cl (14.60/15.25) > H (16.55/16.75).
(iv) Cu(II) complex of 2-thenoyl-pyruv-5-nitroanthranila
mide, 4d, exhibits remarkable extra-potent staphylococcalcidal
action (MIC/MBC= 9.25/10.50 mM), higher than the stan-
dard drug, and thus, can be classiﬁed as a new good candidate
in the ﬁght against PSSA infections. Further studies are
required to explore these complexes as drugs.
In comparison with 2-thenoyl-N-pyruvanthranilic acids
(2a–d), the observed enhanced antibacterial impact of enami-
none esters (3a–e) could be attributed to faster membrane
depolarization by (3a–e) which may be explained by their
greater hydrophobicity. This enhanced depolarization facili-
tates the spontaneous insertion of enaminones into the bacte-
rial membranes, and their conformational ﬂexibility allows
better adaptability to the membrane (Bionda et al., 2012).
The enhanced antibacterial activity of the Cu(II) complexes
can be explained in terms of Overtone’s concept of cell perme-
ability (Dharamaraj et al., 2001) and Tweedy’s Chelation the-
ory (Malhota et al., 1993). Considering these theories, such
antibacterial potency of complexes could be assigned to their
higher liposolubility effect and enhanced cell permeability
owing to diminishing the polarity of the copper ion upon
chelation due to the overlap with the ligand orbitals and par-
tial sharing of the positive charge on the copper ion with donor
atoms. Further, the delocalization of charge/electrons over the
chelate ring enhances the lipophilicity of the complexes. This
increased lipophilicity facilitates penetration of these probes
into lipid membranes with blocking metal binding sites in the
enzymes of microorganisms. These complexes can also disturb
the respiration of bacterial cell and thus inhibit protein synthe-
sis that restricts further bacterial growth.
Although the exact mechanism by which antibacterial Cu(
II)-thenoylpyruvanthranilates complexes (4a–d) exert their
Figure 4 Graph of zone of inhibition (mm) for target compounds against different bacterial species.
Table 2 MIC/MBC (mM) proﬁles of Cu(II) complexes
against different strains.a
Compound MIC/MBC (mM)
S. aureus E. coli
4a 13.75/18.75 16.55/16.75
4b 12.50/14.75 14.60/15.25
3c 12.25/15.25 14.75/14.75
4d 9.25/10.50 13.25/13.50
Am. 12.45/NA 15.10/NA
Am. = Ampicillin (Antibacterial drug).
a S. aureus representative for G+ Bacteria, E. coli as G Bacteria.
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mode of action may involve various targets in microorganisms:
(i) Inhibition of, or interference with cellular envelope biosyn-
thesis inducing envelope damage that can lead to the alteration
of cell permeability or disorganized lipoprotein arrangements
which ultimately resulted in cell death (Mott et al., 2008). (ii)
Hydrogen-bonding interactions of the complex H-receptor
sites (such as anilide, carbonyl and carboxylate fragments)
with active binding sites of cell constituents, resulting in inter-
ference with the normal cell process (Das, 1990). (iii) The redox
cycling between Cu(II) and Cu(I) can catalyze the production
of highly reactive oxygen species (ROS) such as hydroxyl rad-
icals, thus targeting numerous biochemical pathways within
the cell causing oxidation of thiol proteins, DNA damage, lipid
peroxidation and the binding-site displacement of Cu-
containing metalloprotein (Harrison et al., 2008; Stohs and
Bagchi, 1995). Once the Cu(II) complex penetrates the bacte-
rial cell wall, the cellular oxygen oxidizes the protein thiols
(R-SH) followed by a one-electron transfer reduction ofScheme 5 O2
 dismutation mediated by the SOD [CuII/CuIcopper(II) center to produce Cu(I) complex. Further, oxida-
tion of sulfhydryl group in sulfhydryl-containing proteins
(R–S–S–R), such as Cysteine, is another pathway to produce
reduced copper complexes. The Cu(II)/Cu(I) complexes system
exhibits a relatively high superoxide dismutase (SOD)-like
activity, where Cu(I) complex catalyzes the one-electron reduc-
tion of normal dioxygen (O2) to reactive oxygen species (O2
)
and peroxide (H2O2), while Cu(II) complex may catalyze the
dismutation of highly reactive superoxide (O2
) into dioxygen
(O2) (see Scheme 5). The higher reactive oxygen species
(ROS) formed during this cycle, superoxide (O2
) and peroxide
(H2O2), nonspeciﬁcally oxidizes lipids, proteins, nucleic acids,
and sugars, resulting in staphylococcalcidal effect and
E. coli-cidal actions. In addition, the reduced Cu(I) complex
may inhibit DNA synthesizer ATP production through inhibi-
tion of mitochondrial respiration and destruction of cell viabil-
ity. In conclusion, the quasi-reversible one-electron CuII/CuI
redox waves are responsible for the mode of antibacterial
action of copper complexes.
3.4. Bioﬁlm susceptibility
The susceptibility of the bacterial bioﬁlm to serial concentra-
tions of the target complexes was carried out by calculating
the percentage reduction of Alamar blue for treated S. aureus
and E. coli, spectrophotometrically. Interestingly, from Fig. 5,
Cu(II)-TPXA complexes exhibited signiﬁcant MRSA and
MDREC bioﬁlms growth-inhibitory activity at all the exam-
ined concentrations and the percentage reduction of Alamar
blue varies in a dose-dependent proﬁle.
Our data demonstrate a remarkable bioﬁlm-producing resis-
tance by the action of complex 2a ((Reduction %)S. aureus-bioﬁlm
= 6.43 at 20 mM; (Reduction%)E. coli-bioﬁlm = 10.41 at
20 mM), compared with other complexes. Eventually,-complex] redox couple conﬁned in the bacterial species.
Figure 5 Percent reduction of Alamar blue by S. aureus and E. coli bioﬁlms treated with different concentrations of complexes (4a–d).
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[Cu(TPNA)(H2O)2] (4d) may serve as a platform toward discov-
ery of exceptionally active antibiofouling agent to control the
formation of bioﬁlm.
4. Conclusion
The present study shows chemoselective aminolysis of
2-thenoyl-pyruvate 1b with equimolar amounts of anthranilic
acid derivatives in either a single solvent, HOAc, to yield
enaminones (3a–e) or mixed-solvent, HOAc/EtOH (few drops
of HOAc), to give a-keto anthranilides (2a–d). Mononuclear
Cu(II) complexes of anthranilides (2a–d) have been synthesized
from reaction of (2a–d) with Cu(OAc)2ÆH2O. X-ray analyses of
ETCAOB, 3b, reveal the Z form with planar O‚CAC‚CAN
moiety. Antibacterial and antibioﬁlm susceptibility assay of
new copper(II) N-pyruvoyl anthranilate architectures against
bacterial marine isolates, E. Coli and S. aureus, demonstrated
that complex 4d can therefore provide an antibioﬁlm-forming
agent candidate with further chemical reﬁnements.
Consequently, future further study for the antifouling perfor-
mance of 4d and incorporation of it into the bulk of commer-
cial paint may provide a new generation of antifouling paints.Acknowledgments
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